

## PUBLICATIONS

(peer-reviewed)

### Original Articles

1. Atkinson JW, Bongort K, **Price LH**. Explorations using computer simulation to comprehend thematic apperceptive measurement of motivation. Motiv and Emot 1:1-27, 1977.
2. Leigh H, **Price L**, Ciarcia J, Mirassou M. DSM III and consultation-liaison psychiatry: Toward a comprehensive medical model of the patient. Gen Hosp Psychiatry 4:283-289, 1982.
3. **Price LH**, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 140:318-322, 1983.
4. **Price LH**, Nelson JC, Waltrip RW. Desipramine-associated hepatitis. J Clin Psychopharmacol 3:243-246, 1983.
5. **Price LH**, Nelson JC, Charney DS, Quinlan DM. Family history in delusional depression. J Affect Disord 6:109-114, 1984.
6. **Price LH**, Nelson JC, Charney DS, Quinlan DM. The clinical utility of family history for the diagnosis of melancholia. J Nerv Ment Dis 172:5-11, 1984.
7. **Price LH**, Nelson JC, Jatlow PI. Effects of desipramine on clinical liver function tests. Am J Psychiatry 141:798-800, 1984.
8. **Price LH**, Charney DS, Heninger GR. Three cases of manic symptoms following yohimbine administration. Am J Psychiatry 141:1267-1268, 1984.
9. **Price LH**, Charney DS, Heninger GR. Efficacy of lithium-tranlycypromine treatment in refractory depression. Am J Psychiatry 142:619-623, 1985.
10. Rubin AL, **Price LH**, Charney DS, Heninger GR. Noradrenergic function and the cortisol response to dexamethasone in depression. Psychiatr Res 15:5-15, 1985.
11. Rubin AL, Charney DS, **Price LH**, Heninger GR. Rapid improvement of delusional depression following two drug-induced seizures. J Clin Psychiatry 46:146-147, 1985.
12. **Price LH**, Charney DS, Heninger GR. Effects of tranlycypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 37:809-818, 1985.
13. **Price LH**, Charney DS, Heninger GR. Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients. Psychopharmacology 89:38-44, 1986.
14. Mazure C, Nelson JC, **Price LH**. Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry 43:451-456, 1986.
15. Innis RB, Bunney BS, Charney DS, **Price LH**, Glazer WM, Sternberg DE, Rubin AL, Heninger GR. Does the cholecystokinin antagonist proglumide possess antipsychotic activity? Psychiatr Res 18:1-7, 1986.
16. **Price LH**, Charney DS, Rubin AL, Heninger GR. Alpha-2 adrenergic receptor function in depression: The cortisol response to yohimbine. Arch Gen Psychiatry 43:849-858, 1986.
17. Goodman WK, Charney DS, **Price LH**, Woods SW, Heninger GR. Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: Report of three cases. Am J Psychiatry 143:900-903, 1986.
18. Nelson JC, **Price LH**, Jatlow PI. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. Am J Psychiatry 143:1151-1154, 1986.
19. **Price LH**, Charney DS, Heninger GR. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 143:1387-1392, 1986.
20. Charney DS, **Price LH**, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression: Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry 43:1155-1161, 1986.
21. **Price LH**, Goodman WK, Charney DS, Heninger GR. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 144:1059-1061, 1987.
22. **Price LH**, Charney DS, Heninger GR. Reserpine augmentation of desipramine in refractory depression: Clinical and neurobiological effects. Psychopharmacology 92:431-437, 1987.
23. Charney DS, Goodman WK, **Price LH**, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive compulsive disorder: A comparison of the effects of tryptophan and MCPP in patients and healthy subjects. Arch Gen Psychiatry 45:177-185, 1988.

24. **Price LH**, Charney DS, Heninger GR. Effects of trazodone treatment on serotonergic function in depressed patients. Psychiatry Res 24:165-175, 1988.
25. Delgado PL, **Price LH**, Charney DS, Heninger GR. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 15:55-60, 1988.
26. Heninger GR, Charney DS, **Price LH**. Alpha-2-adrenergic receptor function in depression: The plasma MHPG, behavioral, and cardiovascular responses to yohimbine. Arch Gen Psychiatry 45:718-726, 1988.
27. Murburg MM, **Price LH**, Jalali B. Huntington's disease: Therapeutic strategies. Fam Syst Med 6:290-303, 1988.
28. **Price LH**, Delgado PL, Charney DS, Heninger GR. Sequence of drug administration in lithium augmentation: A case study. J Clin Psychiatry 49:161-162, 1988.
29. Salloway S, **Price LH**, Charney DS, Shapiro M. Multiple sclerosis presenting as major depression: A diagnosis suggested by MRI scan but not CT scan. J Clin Psychiatry 49:364-366, 1988.
30. Goodman WK, **Price LH**, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive compulsive disorder: A double-blind comparison with placebo. Arch Gen Psychiatry 46:36-44, 1989.
31. **Price LH**, Charney DS, Delgado PL, Heninger GR. Lithium treatment and serotonergic function: Neuroendocrine, behavioral, and physiologic responses to intravenous L-tryptophan in affective disorder patients. Arch Gen Psychiatry 46:13-19, 1989.
32. **Price LH**, Ricaurte GA, Krystal JH, Heninger GR. Neuroendocrine and mood responses to I.V. L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users: Preliminary findings. Arch Gen Psychiatry 46:20-22, 1989.
33. **Price LH**, Charney DS, Delgado PL, Anderson GM, Heninger GR. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan: Serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 46:625-631, 1989.
34. Goodman WK, **Price LH**, Rasmussen SA, Mazure C, Fleischman R, Hill C, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011, 1989.
35. Goodman WK, **Price LH**, Rasmussen SA, Mazure C, Delgado PL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): II. Validity. Arch Gen Psychiatry 46:1012-1016, 1989.
36. Delgado PL, Charney DS, **Price LH**, Landis H, Heninger GR. Neuroendocrine and behavioral effects of dietary tryptophan depletion in healthy subjects. Life Sci 45:2323-2332, 1989.
37. Seibyl JP, Krystal JH, Goodman WK, **Price LH**. Obsessive-compulsive symptoms in a patient with a right frontal lobe lesion: Response to lithium augmentation of translycypromine. Neuropsychiatry, Neuropsychol, and Behav Neurol 1:295-299, 1989.
38. **Price LH**, Charney DS, Delgado PL, Heninger GR. Lithium and serotonin function: Implications for the serotonin hypothesis of depression. Psychopharmacology 100:3-12, 1990.
39. Nierenberg AA, **Price LH**, Charney DS, Heninger GR. After lithium augmentation: A retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 18:167-175, 1990.
40. Kosten TR, Krystal JH, Charney DS, **Price LH**, Morgan C, Kleber HD. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Dependence 25:73-78, 1990.
41. McDougle CJ, Goodman WK, **Price LH**, Delgado PL, Krystal JH, Charney DS, Heninger GR. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 147:652-654, 1990.
42. Delgado PL, Charney DS, **Price LH**, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411-418, 1990.
43. Goodman WK, **Price LH**, Delgado PL, Palumbo J, Krystal JH, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47:577-585, 1990.
44. **Price LH**, Charney DS, Delgado PL, Heninger GR. Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol 10:312-317, 1990.
45. McDougle CJ, **Price LH**, Goodman, WK. Fluvoxamine treatment of autistic disorder and obsessive compulsive disorder: A case report. J Autism Dev Disorders 20(4):537-543, 1990.

46. Delgado PL, Goodman WK, **Price LH**, Heninger GR, Charney DS. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. *Brit J Psychiatry* 157:762-765, 1990.
47. McDougle CJ, **Price LH**, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: Lack of efficacy. *J Clin Psychopharmacol* 11:175-184, 1991.
48. **Price LH**, Charney DS, Delgado PL, Heninger GR. Serotonin function and depression: Neuroendocrine and mood responses to intravenous L-tryptophan in DSM-III-R depressive subtypes and healthy controls. *Am J Psychiatry* 148:1518-1525, 1991.
49. Seibyl JP, Krystal JH, **Price LH**, Woods SW, D'Amico C, Heninger GR, Charney DS. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. *Psychiatry Res* 38:227-236, 1991.
50. Satel SL, **Price LH**, Palumbo JM, McDougle CJ, Krystal JH, Gawin F, Charney DS, Heninger GR, Kleber HD. The clinical phenomenology and neurobiology of cocaine abstinence: A prospective inpatient study. *Am J Psychiatry* 148:1712-1716, 1991.
51. McCance-Katz EF, **Price LH**, Charney DS, Heninger GR. Serotonergic function during lithium augmentation of refractory depression. *Psychopharmacology* 108:93-97, 1992.
52. McDougle CJ, **Price LH**, Volkmar FR, Goodman WK, Ward-O'Brien D, Nielsen J, Bregman J, Cohen DJ. Clomipramine in autism: Preliminary evidence of efficacy. *J Am Acad Child Adolesc Psychiatry*, 31(4):746-750, 1992.
53. Krystal JH, **Price LH**, Opsahl C, Ricaurte GA, Heninger GR. Chronic 3,4-methylenedioxyamphetamine (MDMA) use: Effects on mood and neuropsychological function? *Am J Drug Alcohol Abuse* 18:331-341, 1992.
54. Krystal JH, McDougle CJ, Woods SW, **Price LH**, Heninger GR, Charney DS. Dose-response relationship for oral idazoxan effects in healthy human subjects: Comparison with oral yohimbine. *Psychopharmacology* 108:313-319, 1992.
55. Krystal JH, McDougle CJ, Kosten TR, **Price LH**, Aghajanian GK, Charney DS. Baclofen-assisted detoxification from opiates: A pilot study. *J Subst Abuse Treatment* 9:139-142, 1992.
56. McDougle CJ, **Price LH**, Palumbo JM, Kosten TR, Heninger GR, Kleber HD. Dopaminergic responsivity during cocaine abstinence. *Psychiatry Res* 43:77-85, 1992.
57. McCance-Katz EF, Marek KL, **Price LH**. Serotonergic dysfunction in depression associated with Parkinson's disease. *Neurology* 42:1813-1814, 1992.
58. Marek GJ, McDougle CJ, **Price LH**, Seiden LS. A comparison of trazodone and fluoxetine: Implications for a serotonergic mechanism of antidepressant action. *Psychopharmacology* 109:2-11, 1992.
59. Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranath C, Roth RH, **Price LH**, Gjedde A, Bunney BS, Sass KJ, Elsworth JD, Kier L, Makuch R, Hoffer PB, Redmond DE. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. *N Engl J Med* 327:1541-1548, 1992.
60. McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz EF, Heninger GR, **Price LH**. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. *Am J Psychiatry* 150:647-649, 1993.
61. McCance-Katz EF, **Price LH**, McDougle CJ, Kosten TR, Black JE, Jatlow PI. Concurrent cocaine-ethanol ingestion in humans: Pharmacology, physiology, behavior, and the role of cocaethylene. *Psychopharmacology* 111:39-46, 1993.
62. McDougle CJ, Naylor ST, Goodman WK, Volkmar FR, Cohen DJ, **Price LH**. Acute tryptophan depletion in autistic disorder: A controlled case study. *Biol Psychiatry* 33:547-550, 1993.
63. Zimmerman RC, McDougle CJ, Schumacher M, Olcese J, Mason JW, Heninger GR, **Price LH**. Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans. *J Clin Endocr Metab* 76:1160-1164, 1993.
64. Krystal JH, Seibyl JP, **Price LH**, Woods SW, Heninger GR, Aghajanian GK, Charney DS. *m*-chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients: Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. *Arch Gen Psychiatry* 50:624-635, 1993.

65. Rosen MI, Pearsall HR, **Price LH**, McDougle CJ, Woods SW, Kosten TR. Carbamazepine vs. oxazepam for benzodiazepine detoxification in methadone-maintained patients. Am J Addictions 2(2):165-168, 1993.
66. Rosen MI, Pearsall HR, McDougle CJ, **Price LH**, Woods SW, Kosten TR. Effects of acute buprenorphine on responses to intranasal cocaine: A pilot study. Am J Drug Alcohol Abuse 19(4):451-464, 1993.
67. McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, **Price LH**. The efficacy of fluvoxamine in obsessive-compulsive disorder: Effects of comorbid chronic tic disorder. J Clin Psychopharmacol 13:354-358, 1993.
68. Calvocoressi L, McDougle CJ, Wasylink S, Goodman WK, **Price LH**. Hospital treatment of patients with severe obsessive compulsive disorder. Hosp Community Psychiatry 44:1150-1154, 1993.
69. Zimmermann RC, McDougle CJ, Schumacher M, Olcese J, Heninger GR, **Price LH**. Urinary 6-hydroxymelatonin sulfate as a measure of melatonin secretion during acute tryptophan depletion. Psychoneuroendocrinology 18:567-578, 1993.
70. Wexler BE, Levenson L, Warrenburg S, **Price LH**. Decreased perceptual sensitivity to emotion-evoking stimuli in depression. Psychiatry Res 51:127-138, 1994.
71. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, **Price LH**. Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308, 1994.
72. Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS, **Price LH**. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 51:309-317, 1994.
73. Holzer JC, Goodman WK, McDougle CJ, Baer L, Boyarsky BK, Leckman JF, **Price LH**. Obsessive compulsive disorder with and without a chronic tic disorder: A comparison of symptoms in 70 patients. Br J Psychiatry 164:469-473, 1994.
74. Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, **Price LH**, Kosten TR. Buprenorphine: Duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Dependence 35:141-149, 1994.
75. **Price LH**, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 331:591-598, 1994.
76. McDougle CJ, Black JE, Malison RT, Zimmermann RC, Kosten TR, Heninger GR, **Price LH**. Noradrenergic dysregulation during cocaine abstinence in cocaine addicts: biochemical, behavioral, and cardiovascular correlates. Arch Gen Psychiatry 51:713-719, 1994.
77. Leckman JF, Goodman WK, North W, Chappell PB, **Price LH**, Pauls DL, Anderson GM, Riddle MA, McSwiggan-Hardin M, McDougle CJ, Barr LC, Cohen DJ. Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder patients: Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry 51:782-792, 1994.
78. Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR, **Price LH**. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 151:1626-1630, 1994.
79. Epperson CN, McDougle CJ, Anand A, Marek GJ, Naylor ST, Volkmar FR, Cohen DJ, **Price LH**. Lithium augmentation of fluvoxamine in autistic disorder: A case report. J Child Adolesc Psychopharmacology 4:201-207, 1994.
80. Delgado PL, **Price LH**, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, Charney DS. Serotonin and the neurobiology of depression: Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51:865-874, 1994.
81. Leckman JF, Goodman WK, North WG, Chappell PB, **Price LH**, Pauls DL, Anderson GM, Riddle MA, McDougle CJ, Barr LJ, Cohen DJ. The role of central oxytocin in obsessive compulsive disorder and related behavior. Psychoneuroendocrinology 19:723-749, 1994.
82. Goddard AW, Sholomskas DE, Walton KE, Augeri FM, Charney DS, Heninger GR, Goodman WK, **Price LH**. Effects of tryptophan depletion in panic disorder. Biol Psychiatry 36:775-777, 1994.
83. Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, Van Dyck CC, **Price LH**, Zubal G, Hofer PB, Charney DS. Opiate dependence and withdrawal: Preliminary assessment using single photon emission computerized tomography (SPECT). Am J Drug Alcohol Abuse 21:47-63, 1995.

84. Anand A, Malison R, McDougle CJ, **Price LH**. Antiglucocorticoid treatment of refractory depression with ketoconazole: A case report. Biol Psychiatry 37:338-340, 1995.
85. Calvocoressi L, Lewis B, Kennedy M, Goodman WK, Trufan SJ, McDougle CJ, **Price LH**. Family accommodation in obsessive-compulsive disorder. Am J Psychiatry 152:441-443, 1995.
86. Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL, Cohen DJ, **Price LH**. CSF biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 12:73-86, 1995.
87. McDougle CJ, Kresch LE, Goodman WK, Naylor ST, Volkmar FR, Cohen DJ, **Price LH**. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 152:772-777, 1995.
88. McDougle CJ, Krystal JH, **Price LH**, Heninger GR, Charney DS. Noradrenergic response to acute ethanol administration in healthy subjects: Comparison with intravenous yohimbine. Psychopharmacology 118:127-135, 1995.
89. Hameedi FA, Rosen MI, McCance-Katz EF, McMahon TJ, **Price LH**, Jatlow PI, Woods SW, Kosten TR. Behavioral, physiological, and pharmacological interactions of cocaine and disulfiram in humans. Biol Psychiatry 37:560-563, 1995.
90. Aronson SC, Black JE, McDougle CJ, Stanley BE, Jatlow P, Kosten TR, Heninger GR, **Price LH**. Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology 119:179-185, 1995.
91. McCance EF, **Price LH**, Kosten TR, Jatlow PI. Cocaethylene: Pharmacology, physiology, and behavioral effects in humans. J Pharmacol Exp Ther 274:215-223, 1995.
92. Goddard AW, Charney DS, Germaine M, Woods SW, Heninger GR, Krystal JH, Goodman WK, **Price LH**. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biol Psychiatry 38:74-85, 1995.
93. Malison RT, McDougle CJ, van Dyck C, Scahill L, Baldwin RM, Seibyl JP, **Price LH**, Leckman JF, Innis RB. [<sup>123</sup>I]b-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 152:1359-1361, 1995.
94. Goodman WK, McDougle CJ, **Price LH**, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR. M-chlorophenylpiperazine in patients with obsessive compulsive disorder: Absence of symptom exacerbation. Biol Psychiatry 38:138-149, 1995.
95. **Price LH**, Spencer DD, Marek KL, Robbins RJ, Leranath C, Farhi A, Naftolin F, Roth RH, Bunney BS, Hoffer PB, Makuch R, Redmond DE. Psychiatric status after human fetal mesencephalic transplantation in Parkinson's disease. Biol Psychiatry 38:498-505, 1995.
96. Sass KJ, Buchanan CP, Westerveld M, Marek KL, Farhi A, Robbins RJ, Naftolin F, Vollmer TL, Leranath C, Roth RH, **Price LH**, Bunney BS, Elsworth JD, Hoffer PB, Redmond DE, Spencer DD. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Arch Neurology 52:680-686, 1995.
97. McDougle CJ, Fleischmann RL, Epperson CN, Wasyluk S, Leckman JF, **Price LH**. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: Three cases. J Clin Psychiatry 56:526-528, 1995.
98. McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, **Price LH**. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 152:1812-1814, 1995.
99. McDougle CJ, Brodtkin ES, Yeung PP, Naylor ST, Cohen DJ, **Price LH**. Risperidone in adults with autism or pervasive developmental disorders. J Child Adolesc Psychopharmacology 5:273-282, 1995.
100. Cappiello A, McDougle CJ, Malison RT, Heninger GR, **Price LH**. Yohimbine augmentation of fluvoxamine in refractory depression: A single-blind study. Biol Psychiatry 38:765-767, 1995.
101. Malison RT, Best SE, Wallace EA, McCance E, Laruelle M, Zoghbi SS, Baldwin RM, Seibyl JS, Hoffer PB, **Price LH**, Kosten TR, Innis RB. Euphorogenic doses of cocaine reduce [<sup>123</sup>I]b-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology 122:358-362, 1995.
102. Kosten TR, Kosten TA, McDougle CJ, Hameedi FA, Rosen MI, Oliveto A, **Price LH**. Gender differences in response to intranasal cocaine administration. Biol Psychiatry 39:147-148, 1996.
103. Epperson CN, McDougle CJ, **Price LH**. Intranasal oxytocin in obsessive compulsive disorder. Biol Psychiatry 40:547-549, 1996.

104. Capiello A, Malison RT, McDougle CJ, Vegso S, Charney DS, Heninger GR, **Price LH**. Seasonal variation in neuroendocrine and mood responses to i.v. L-tryptophan in depressed patients and healthy subjects. Neuropsychopharmacology 15:475-483, 1996.
105. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, **Price LH**. Effects of tryptophan depletion in drug-free adults with autism. Arch Gen Psychiatry 53:993-1000, 1996.
106. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, **Price LH**. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008, 1996.
107. Rasmussen AM, Anderson GM, Lynch KA, McSwiggan-Hardin M, Scahill LD, Mazure CM, Goodman WK, **Price LH**, Cohen DJ, Leckman JF. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry 41:117-121, 1997.
108. Kirwin PD, Anderson GM, Chappell PB, Saberski L, Leckman JF, Geraciotti TD, Heninger GR, **Price LH**, McDougle CJ. Assessment of diurnal variation of cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in healthy human females. Life Sci 60:899-907, 1997.
109. Barr LC, Heninger GR, Goodman W, Charney DS, **Price LH**. Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry 41:949-954, 1997.
110. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, Bronen RA, Krystal JH, Duncan J, Rich D, **Price LH**, Malison R, Dey H, Soufer R, Charney DS. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 54:364-374, 1997.
111. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, **Price LH**, Cohen DJ. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693, 1997.
112. Barr LC, Goodman WK, Anand A, McDougle CJ, **Price LH**. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 154:1293-1295, 1997.
113. **Price LH**, Capiello A, Malison RT, McDougle CJ, Pelton GH, Schöllnhammer G, Heninger GR. Effects of antigluco-corticoid treatment on 5-HT<sub>1A</sub> function in depressed patients and healthy subjects. Neuropsychopharmacology 17:246-257, 1997.
114. **Price LH**, Malison RT, McDougle CJ, McCance-Katz EF, Owen K, Heninger GR. The neurobiology of tryptophan depletion in depression: Effects of m-chlorophenylpiperazine (mCPP). Neuropsychopharmacology 17:342-350, 1997.
115. Brodtkin ES, McDougle CJ, Naylor ST, Cohen DJ, **Price LH**. Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation. J Child Adolesc Psychopharmacology 7:109-121, 1997.
116. Gelernter J, van Dyck C, van Kammen DP, Malison R, **Price LH**, Cubells J, Berman R, Charney DS, Heninger G. Ciliary neurotrophic factor null allele frequency in schizophrenia, affective disorders, and Alzheimer's disease. Am J Med Genet (Neuropsych Genet) 74:497-500, 1997.
117. Capiello A, Sernyak M, Malison RT, McDougle CJ, Heninger GR, **Price LH**. Effects of acute tryptophan depletion in lithium-remitted manic patients: Preliminary findings. Biol Psychiatry 42:1076-1078, 1997.
118. Calvocoressi L, Libman D, Vegso S, McDougle CJ, **Price LH**. Global functioning in obsessive-compulsive disorder: A preliminary comparison with schizophrenia and major depression. Psychiatr Serv 49:379-381, 1998.
119. McDougle CJ, Brodtkin ES, Naylor ST, Carlson DC, Cohen DJ, **Price LH**. Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. J Clin Psychopharmacology 18:62-66, 1998.
120. Narayan M, Anderson G, Cellar J, Malison RT, **Price LH**, Nelson JC. Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacology 18:67-71, 1998.
121. **Price LH**, Malison RT, McDougle CJ, Pelton GH, Heninger GR. The neurobiology of tryptophan depletion in depression: Effects of intravenous tryptophan infusion. Biol Psychiatry 43:339-347, 1998.

122. Carpenter LL, Anderson GM, Pelton GH, Gudín JA, Kirwin PD, **Price LH**, Heninger GR, McDougale CJ. Tryptophan depletion during continuous CSF sampling via indwelling lumbar catheter in healthy human subjects. Neuropsychopharmacology 19:26-35, 1998.
123. Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, **Price LH**, Kosten TE, Innis RB. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [<sup>123</sup>I]b-CIT SPECT. Am J Psychiatry 155:832-834, 1998.
124. McDougale CJ, Epperson CN, **Price LH**, Gelernter JE. Evidence for linkage disequilibrium between serotonin transporter protein (SLC6A4) and obsessive compulsive disorder. Molec Psychiatry 3:270-273, 1998
125. Kosten TR, Cheeves C, Palumbo J, Seibyl JP, **Price LH**, Woods SW. Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse. Drug Alcohol Dependence 50:187-195, 1998.
126. McDougale CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, **Price LH**. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-641, 1998.
127. Sernyak MJ, Glazer WM, Heninger GR, Charney DS, Woods SW, Petrakis IL, Krystal JH, **Price LH**. Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacology 18:248-251, 1998.
128. Cubells JF, van Kammen DP, Kelley ME, Anderson GM, O'Connor DT, **Price LH**, Malison R, Rao PA, Kobayashi K, Nagatsu T, Gelernter J. Dopamine β-hydroxylase: Two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genetics 102:533-540, 1998.
129. Cappiello A, McDougale CJ, Delgado PL, Malison RT, Jatlow P, Charney DS, Heninger GR, **Price LH**. Lithium+desipramine vs. desipramine alone in the treatment of severe major depression: A preliminary study. Int Clin Psychopharmacology 13:191-198, 1998.
130. Malison RT, **Price LH**, Berman R, van Dyck CJ, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced brain serotonin transporter availability in major depression as measured by [<sup>123</sup>I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 44:1090-1098, 1998.
131. Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, **Price LH**, Kosten TR, Innis RB. [<sup>123</sup>I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology 137(4):321-325, 1998.
132. Carpenter LL, Jovic Z, Hall JM, Rasmussen SA, **Price LH**. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60:45-49, 1999.
133. McDougale CJ, Barr LC, Goodman WK, **Price LH**. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24:1-24, 1999.
134. Carpenter LL, Jovic Z, Yasmin S, **Price LH**. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 11:81-86, 1999.
135. Bruder GE, Wexler BE, Stewart JE, **Price LH**, Quitkin FM. Perceptual asymmetry differences between major depression with or without a comorbid anxiety disorder: A dichotic listening study. J Abnorm Psychology 108:233-239, 1999.
136. Goddard AW, Woods SW, Money R, Pande AC, Charney DS, Goodman WK, Heninger GR, **Price LH**. Effects of the CCK<sub>B</sub> antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res 85:225-240, 1999.
137. Epperson CN, Fasula D, Wasyluk S, **Price LH**, McDougale CJ. Risperidone addition in serotonin uptake inhibitor-resistant trichotillomania: Three cases. J Child Adolesc Psychopharmacology 9:43-49, 1999.
138. Longhurst JG, Carpenter LL, Epperson CN, **Price LH**, McDougale CJ. Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder. Biol Psychiatry 46:573-576, 1999.
139. Malison RT, Anand A, Pelton GH, Kirwin P, Carpenter L, McDougale CJ, Heninger GR, **Price LH**. Limited efficacy of ketoconazole in treatment refractory major depression. J Clin Psychopharmacology 19:466-470, 1999.

140. Calvocoressi L, Mazure C, Kasl S, Skolnick J, Fisk D, Vegso S, Van Noppen B, **Price LH**. Family accommodation of obsessive-compulsive symptoms: Instrument development and assessment of family behavior. J Nerv Ment Dis 187:636-642, 1999.
141. Cubells JF, Kranzler HR, McCance-Katz E, Anderson GM, Malison RT, **Price LH**, Gelernter J. A haplotype at the DBH locus, associated with low plasma dopamine b-hydroxylase activity, also associates with cocaine-induced paranoia. Molec Psychiatry 5:56-63, 2000.
142. Desan PH, Oren DA, Malison R, **Price LH**, Rosenbaum J, Smoller J, Charney DS, Gelernter J. Genetic polymorphism at the *CLOCK* gene locus and major depression. Am J Med Genet (Neuropsychiatr Genet) 96:418-421, 2000.
143. McDougle CJ, Epperson CN, Pelton GH, Wasyluk S, **Price LH**. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive compulsive disorder. Arch Gen Psychiatry 57:794-801, 2000.
144. Gagne GG Jr, Furman MJ, Carpenter LL, **Price LH**. The efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psychiatry 157:1960-1965, 2000.
145. Yasmin S, Carpenter LL, Leon Z, Siniscalchi JM, **Price LH**. Adjunctive gabapentin in treatment-resistant depression: A retrospective chart review. J Aff Disord 63:243-247, 2001.
146. Eisen JL, Rasmussen SA, Phillips KA, **Price LH**, Davidson J, Lydiard RB, Ninan P, Piggott T. Insight and treatment outcome in obsessive compulsive disorder. Compr Psychiatry 42:494-497, 2001.
147. Eisen JL, Leonard H, Swedo S, **Price LH**, Zabriskie JB, Chiang SY, Karitani M, Rasmussen SA. Antibody D8/17 identification of B cells in adults with obsessive compulsive disorder. Psychiatry Res 104:221-225, 2001.
148. Carpenter LL, Yasmin S, **Price LH**. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51:183-188, 2002.
149. Cubells JF, **Price LH**, Meyers BS, Anderson GM, Zabetian CP, Alexopoulos GS, Nelson JC, Sanacora G, Kirwin P, Carpenter L, Malison RT, Gelernter J. Genotype-controlled analysis of plasma dopamine  $\beta$ -hydroxylase activity in psychotic unipolar depression. Biol Psychiatry 51:358-364, 2002.
150. Carpenter LL, Leon Z, Yasmin S, **Price LH**. Do obese depressed patients respond to topiramate? A retrospective review. J Aff Disord 69:251-255, 2002.
151. Lappalainen J, Kranzler HR, Malison R, **Price LH**, Van Dyck C, Rosenheck RA, Cramer J, Southwick S, Charney D, Krystal J, Gelernter J. A functional neuropeptide Y Leu7Pro polymorphism is associated with alcohol dependence in a large population sample from the U.S. Arch Gen Psychiatry 59:825-831, 2002.
152. Carpenter LL, Heninger GR, McDougle CJ, RT, Tyrka AR, Epperson CN, **Price LH**. Cerebrospinal fluid interleukin (IL)-6 in obsessive-compulsive disorder and trichotillomania. Psychiatry Res 112:257-262. 2002.
153. Carpenter LL, Anderson GM, Siniscalchi JM, Chappell PB, **Price LH**. Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. Neuropsychopharmacology 28(2):339-347, 2003.
154. Marek, GJ, Carpenter LL, McDougle CJ, **Price LH**. Synergistic action of 5-HT<sub>2A</sub> antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28(2):402-412, 2003.
155. Giambalvo CT, **Price LH**. Effects of fenfluramine and antidepressants on protein kinase C activity in rat cortical synaptoneuroosomes. Synapse 50:212-222, 2003.
156. de Mello AAF, de Mello MF, Carpenter LL, **Price LH**. Update on stress and depression: The role of the hypothalamic-pituitary-adrenal (HPA) axis. Rev Bras Psiquiatr 25(4):231-238, 2003.
157. Lappalainen J, Sanacora G, Kranzler HR, Malison R, Hibbard ES, **Price LH**, Krystal J, Gelernter J. Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. Am J Med Genet (Neuropsychiatr Genet) 124B(1):81-86, 2004.
158. Nelson JC, Mazure CM, Bowers MB, Jr, Jatlow PI, **Price LH**. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatry 55:296-300, 2004.
159. Carpenter LL, Heninger GR, Malison RT, Tyrka AR, **Price LH**. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Aff Disord 79:285-289, 2004.

160. Carpenter LL, Tyrka AR, McDougle CJ, Malison RT, Owens MJ, Nemeroff CB, **Price LH**. Cerebrospinal fluid corticotrophin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology 29(4):777-784, 2004.
161. Najjar F, Welch C, Grapentine WL, Sachs H, Siniscalchi J, **Price LH**. Trends in psychotropic drug use in a child psychiatric hospital from 1991 through 1998. J Child Adol Psychopharmacology 14(1):87-93, 2004.
162. Carpenter LL, Moreno FA, Kling MA, Anderson GM, Regenold WT, Labiner DM, **Price LH**. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biol Psychiatry 56(6):418-426, 2004.
163. Tyrka AR, Carpenter LL, McDougle CJ, Kirwin PD, Owens MJ, Nemeroff CB, Strong DR, **Price LH**. Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. Biol Psychiatry 56(7):531-534, 2004.
164. Carpenter LL, Schechter JM, Underwood JA, Tyrka, AR, **Price LH**. Service expectations and clinical characteristics of patients receiving psychiatric emergency services. Psychiatr Serv 56(6):743-745, 2005.
165. Phillips KA, Grant JE, Siniscalchi JM, Stout R, **Price LH**. A retrospective follow-up study of body dysmorphic disorder. Compr Psychiatry 46(5):315-321, 2005.
166. Carpenter LL, Milosavljevic N, Schechter JM, Tyrka AR, **Price LH**. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry 66(10):1234-1238, 2005.
167. Carpenter LL, Schechter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R, **Price LH**. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 67:66-71, 2006.
168. Geraciotti TD, Carpenter L, Owens MJ, Baker DG, Ekhaton NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, **Price LH**, Nemeroff CB. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 163:637-643, 2006.
169. Zhang H, Ozbay F, Lappalainen J, Kranzler HR, van Dyck CH, Charney DS, **Price LH**, Southwick S, Yang BZ, Rasmussen A, Gelernter J. Brain derived neurotrophic factor (BDNF) genetic variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia and substance dependence. Am J Med Genet B Neuropsychiatr Genet 141B:387-393, 2006.
170. Tyrka AR, Mello AF, Mello MF, Gagne GG, Grover KE, Anderson GM, **Price LH**, Carpenter LL. Temperament and hypothalamic-pituitary-adrenal axis function in healthy adults. Psychoneuroendocrinology 31(9):1036-1045, 2006.
171. Tyrka AR, Wier LM, Anderson GM, Wilkinson CW, **Price LH**, Carpenter LL. Temperament and response to the Trier Social Stress Test. Acta Psychiatr Scand 115:395-402, 2007.
172. Grover KE, Carpenter LL, **Price LH**, Gagne GG, Mello AF, Mello MF, Tyrka AR. The relationship between childhood abuse and adult personality disorder symptoms. J Personal Disord 21(4):442-447, 2007.
173. Carpenter LL, Carvalho JP, Tyrka AR, Wier LM, Mello AF, Mello MF, Anderson GM, Wilkinson CW, **Price LH**. Decreased adrenocorticotropic hormone and cortisol responses to stress in healthy adults reporting significant childhood maltreatment. Biol Psychiatry 62(10):1080-1087, 2007.
174. Carpenter LL, Bayat L, Moreno F, Kling MA, **Price LH**, Kinkead B, Owens MJ, Nemeroff CB. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Res 157:123-129, 2008.
175. Philip NS, Carpenter LL, Tyrka AR, **Price LH**. Augmentation of antidepressants with atypical neuroleptics: A review of the current literature. J Psychiatr Pract 34(1):34-44, 2008.
176. Kelly MM, Tyrka AR, Anderson GA, **Price LH**, Carpenter LL. Sex differences in emotional and physiological responses to the Trier Social Stress Test. J Behav Ther Exp Psychiatry 39(1):87-98, 2008.
177. Rikhye K, Tyrka AR, Kelly MM, Gagne GG Jr, Mello AF, Mello MF, **Price LH**, Carpenter LL. Interplay between childhood maltreatment, parental bonding, and gender effects: Impact on quality of life. Child Abuse Negl 32:19-34, 2008.
178. Philip NS, Mello K, Carpenter LL, Tyrka AR, **Price LH**. Patterns of quetiapine use in psychiatric inpatients: An examination of off-label use. Ann Clin Psychiatry 20(1):15-20, 2008.

179. Tyrka AR, Wier LM, **Price LH**, Rikhye K, Ross NS, Anderson GM, Wilkinson CW, Carpenter LL. Cortisol and ACTH responses to the Dex/CRH test: Influence of temperament. Horm Behav 53(4):518-525, 2008.
180. Tyrka AR, Wier LM, **Price LH**, Ross NS, Anderson GM, Wilkinson CW, Carpenter LL. Childhood parental loss and adult hypothalamic-pituitary-adrenal function. Biol Psychiatry 63(12):1147-1154, 2008.
181. Abrantes AM, Strong DR, Lejuez CW, Kahler CW, Carpenter LL, **Price LH**, Niaura R, Brown RA. The role of negative affect in risk for early lapse among low distress tolerance smokers. Addict Behav 33:1394-1401, 2008.
182. Kelly MM, Tyrka AR, **Price LH**, Carpenter LL. Sex differences in the use of coping strategies: Predictors of anxiety and depressive symptoms. Depress Anxiety 25:839-846, 2008.
183. **Price LH**, Carpenter LL, Tyrka AR. Lithium augmentation for refractory depression: A critical reappraisal. Prim Psychiatry 25(11):35-42, 2008.
184. Tyrka AR, Wier L, **Price LH**, Ross NS, Carpenter LL. Childhood parental loss and adult psychopathology: Effects of loss characteristics and contextual factors. Int J Psychiatry Med 38(3):329-344, 2008.
185. Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, **Price LH**, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 65(4):267-275, 2009.
186. Tyrka AR, Wyche MC, Kelly MM, **Price LH**, Carpenter LL. Childhood maltreatment and adult personality disorder symptoms: Influence of maltreatment type. Psychiatry Res 165:281-287, 2009.
187. Brown, RA, Lejuez CW, Strong DR, Kahler CW, Zvolensky MJ, Carpenter LL, Niaura R, **Price LH**. A prospective examination of distress tolerance and early smoking lapse in adult self-quitters. Nicotine Tob Res 11(5):493-502, 2009.
188. Zuo L, Luo X, Listman JB, Kranzler HR, Wang S, Anton RF, Blumberg HP, Stein MB, Pearlson GD, Covault J, Charney DS, van Kammen DP, **Price LH**, Lappalainen J, Cramer J, Krystal JH, Gelernter J. Population admixture modulates risk for alcohol dependence. Hum Genet 125(5-6):605-613, 2009.
189. Carpenter LL, Tyrka AR, Ross NS, Anderson GM, **Price LH**. Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. Biol Psychiatry 66(1):69-75, 2009.
190. Carpenter LL, Ross NS, Tyrka AR, Anderson GM, Kelly M, **Price LH**. Dex/CRH cortisol response in outpatients with major depression and matched healthy controls. Psychoneuroendocrinology 34:1208-1213, 2009.
191. Philip NS, Carpenter LL, Tyrka AR, Whiteley L, **Price LH**. Varenicline augmentation in depressed smokers: An 8-week, open-label study. J Clin Psychiatry 70(7):1026-1031, 2009.
192. Tyrka AR, **Price LH**, Gelernter J, Schepker C, Anderson G, Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: Effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry 66(7):681-685, 2009.
193. Amin Z, Kanarek K, Krupitsky E, Walderhaug E, Ilomäki R, Blumberg H, **Price LH**, Bhagwagar Z, Carpenter LL, Tyrka AR, Magnusson A, Landrø NI, Zvartau E, Gelernter J, Epperson NE, Räsänen P, Siirinen J, Lappalainen J. A sequencing-based survey of functional *APAF1* alleles in a large sample of individuals with affective illness and population controls. Am J Med Genet B Neuropsychiatr Genet. 153B(1):332-335, 2009.
194. Tyrka AR, **Price LH**, Kao H-T, Porton B, Marsella SA, Carpenter LL. Childhood maltreatment and telomere shortening: Preliminary support for an effect of early stress on cellular aging. Biol Psychiatry 67(6):531-534, 2010.
195. Philip N, Carpenter LL, Tyrka AR, **Price LH**. Pharmacologic approaches to treatment resistant depression: A re-examination for the modern era. Expert Opin Pharmacother 11(5):709-722, 2010.
196. Schoedl AF, Costa MCP, Mari JJ, Mello MF, Tyrka AR, Carpenter LL, **Price LH**. The clinical correlates of reported childhood sexual abuse: An association between age at trauma onset and severity of depression and PTSD in adults. J Child Sex Abuse 19(2):156-170, 2010.
197. Storch EA, Larson MJ, **Price LH**, Rasmussen SA, Murphy TK, Goodman WK. Psychometric analysis of the Yale-Brown Obsessive-Compulsive Scale Second Edition Symptom Checklist. J Anxiety Disord 24(6):650-656, 2010.

198. Storch EA, Rasmussen SA, **Price LH**, Larson MJ, Murphy TK, Goodman WK. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale Second Edition. Psychol Assess 22(2):223-232, 2010.
199. Hitsman B, Shen B-J, Cohen RA, Morissette SB, Drobles DJ, Spring B, Schneider K, Evans DE, Gulliver SB, Kamholz BW, **Price LH**, Niaura N. Measuring smoking-related preoccupation and compulsive drive: Evaluation of the Obsessive Compulsive Smoking Scale. Psychopharmacology 211(4):377-387, 2010.
200. Philip N, Carpenter LL, Tyrka AR, **Price LH**. Nicotinic acetylcholine receptors and depression: A review of the preclinical and clinical literature. Psychopharmacology 212(1):1-12, 2010.
201. Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, **Price LH**. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology. 35(13):2617-2623, 2010.
202. Carpenter LL, Shattuck TT, Tyrka AR, Geraciotti TM, **Price LH**. Effect of childhood physical abuse on cortisol stress response. Psychopharmacology. 2010 Sep 14. [Epub ahead of print].
203. Nugent NR, Tyrka AR, Carpenter LL, Price LH. Gene-environment interactions: Early life stress and risk for depressive and anxiety disorders. Psychopharmacology. In press.
204. Hirschfeld RMA, Keck PE, Gitlin MJ, **Price LH**, Sajatovic M, Suppes T, Thase ME, Perlis RH; American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder, third edition. Am J Psychiatry. In review.
205. Cui DH, Yang BZ, Kranzler HR, Listman JB, Zhang H, Li D, **Price LH**, Carpenter LL, Tyrka AR, Gelernter J. Variation in NGFB is associated with primary affective disorders in women. In review.
206. Carpenter LL, Tyrka AR, Marsella SA, Wilkinson CW, Geraciotti TD, **Price LH**. Eszopiclone treatment and decreased cortisol response in adults with primary insomnia. In review.
207. Carpenter LL, Tyrka AR, Lee JK, Tracy AP, Wilkinson CW, **Price LH**. A placebo-controlled study of sertraline's effect on cortisol response to the Dex/CRH test in healthy adults. In review.
208. Tyrka AR, **Price LH**, Marsit C, Walters C, Wilkinson CW, Carpenter LL. Epigenetic modulation of leukocyte glucocorticoid receptor in healthy adults: Effects of childhood parenting experiences. In review.
209. McGuire JF, Storch EA, Lewin AB, **Price LH**, Rasmussen SA, Goodman WK. The influence of avoidance on symptom severity in adults with obsessive-compulsive disorder. In preparation.
210. Carpenter LL, Carvalho JP, Kelly MM, Tyrka AR, **Price LH**. Does a history of childhood maltreatment influence recall of responses to a psychosocial stress task? In preparation.

#### OTHER PUBLICATIONS

(non-peer-reviewed)

#### Reviews, Chapters, Books:

1. Atkinson JW, Bongort K, **Price LH**. Explorations using computer stimulation to comprehend thematic apperceptive measurement of motivation. Chapter in: Personality, Motivation and Action: Selected Papers, Atkinson JW, Praeger Publishers, New York, pp 311-337, 1983.
2. **Price LH**. Distinguishing clinical from nonclinical depression. Physician and Patient 2:10-23, 1983.
3. Nelson JC, **Price LH**. Psychopharmacology. Chapter in: Psychiatry: Pretest Self-Assessment and Review, 3rd ed, Nelson JC, Greenfeld D. (eds), McGraw-Hill, Inc, New York, pp 158-183, 1984.
4. **Price LH** (Primary consultant). Beta-blockers for anxiety. Medical Letter 26:61-62, June 22, 1984.
5. **Price LH**, Charney DS. Receptor sensitivity in depression. Psychiatry Letter 4:71-76, 1986.
6. Charney DS, Heninger GR, **Price LH**, Breier A. Major depression and panic disorder: Diagnostic and neurobiological relationships. Psychopharm Bull 22:503-511, 1986.
7. Atkinson JW, Bongort K, **Price LH**. Explorations using computer stimulation to comprehend thematic apperceptive measurement of motivation. Chapter in: Motivation, Thought, and Action, Kuhl J, Atkinson JW. (eds), Praeger Publishers, New York, pp 97-124, 1986.
8. Goodman WK, Charney DS, Heninger GR, **Price LH**, Woods SW. Clinical spectrum of action of tricyclic antidepressants: Possible relationships to receptor actions. Chapter in: Biological Psychiatry 1985 (Proceedings of the IVth World Congress of Biological Psychiatry), Shagass C,

- Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM. (eds), Elsevier Science Publishing, New York, pp 906-908, 1986.
9. **Price LH** (Consultant). Psychiatric aspects of chronic pain. Chapter in: Pain and Disability: Clinical, Behavioral, and Public Policy Perspectives, Committee on Pain, Disability, and Chronic Illness Behavior, Institute of Medicine, National Academy Press, Washington, DC, pp 165-185, 1987.
  10. **Price LH**. Antidepressants. Chapter in: Depression & Mania: Modern Lithium Therapy, Johnson FN (ed), IRL Press, Oxford, UK, pp 161-166, 1987.
  11. Charney DS, Woods SW, **Price LH**, Goodman WK, Glazer WM, Heninger GR. Specificity of noradrenergic dysregulation in panic disorder. Chapter in: Progress in Catecholamine Research, Part C: Clinical Aspects, Belmaker RH, Sandler M, Dahlstrom A (eds), Alan R Liss, Inc, New York, pp 343-347, 1988.
  12. Goodman WK, Charney DS, Rasmussen SA, **Price LH**, Woods SW, Heninger GR. Role of noradrenergic and serotonergic systems in obsessive compulsive disorder: Findings from pharmacological challenge studies. Chapter in: Progress in Catecholamine Research, Part C: Clinical Aspects, Belmaker RH, Sandler M, Dahlstrom A (eds), Alan R Liss, Inc, New York, pp 369-375, 1988.
  13. **Price LH** (Primary consultant). Fluoxetine for depression. Medical Letter 30:45-47, April 22, 1988.
  14. Heninger GR, Charney DS, **Price LH**. Noradrenergic and serotonergic receptor system function in panic disorder and depression. Acta Psychiatr Scand 77(Supp 341):138-150, 1988.
  15. **Price LH**. Aggression and violence: A medical approach to pharmacological treatment. Yale Psychiatr Quart 10:5-8, 1988.
  16. Goodman WK, **Price LH**. Antidepressants in obsessive compulsive disorder. Yale Psychiatr Quart 11:8-12, 1988.
  17. **Price LH**. Lithium augmentation of tricyclic antidepressants. Chapter in: Treatment of Tricyclic Resistant Depression, Extein I (ed), American Psychiatric Press, Washington, DC, pp 49-79, 1989.
  18. Goodman WK, **Price LH**, Charney DS. Fluvoxamine in obsessive compulsive disorder. Psychiatr Ann 19:92-96, 1989.
  19. Heninger GR, Charney DS, **Price LH**, Delgado P, Woods S, Goodman W. Effects of serotonergic agonists on neuroendocrine responses in rhesus monkeys and patients with depression and anxiety disorders. Chapter in: Clinical Pharmacology in Psychiatry, Dahl SG, Gram LG (eds), Springer-Verlag, Berlin, pp 94-104, 1989.
  20. Goodman WK, **Price LH**, Rasmussen SA, Heninger GR, Charney DS. Fluvoxamine as an antiobsessional agent. Psychopharmacol Bull 25:31-35, 1989.
  21. Heninger GR, Charney D, **Price L**, Delgado P, Woods S, Goodman W. Neuroendocrine effects of serotonin agonists in rhesus monkeys, healthy humans, and patients with depression or anxiety disorders: Effects of antidepressant treatment. Chapter in: Serotonin: From Cell Biology to Pharmacology and Therapeutics, Paoletti R, et al (eds), Kluwer Academic Publishers, pp 559-563, 1990.
  22. **Price LH**. Pharmacological strategies in refractory depression. Chapter in: American Psychiatric Press Annual Review of Psychiatry, Vol 9, Tasman A, Goldfinger S M, Kaufmann CA, (eds), American Psychiatric Press, Washington, DC, pp 116-131, 1990.
  23. **Price LH**, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. J Clin Psychiatry 51(4, suppl):44-50, 1990.
  24. Charney DS, Woods SW, **Price LH**, Goodman WK, Glazer WM, Heninger GR. Noradrenergic dysregulation in panic disorder. Chapter in: Neurobiology of Panic Disorder, Ballenger JC (ed), Alan R Liss, Inc, New York, NY, pp 91-105, 1990.
  25. Goodman WK, **Price LH**. Rating scales for obsessive compulsive disorder. Chapter in: Obsessive Compulsive Disorders: Theory and Management, 2nd Ed, Jenike MJ, Baer L, Minichiello WE (eds), PSG Publishing Co, Littleton, MA, pp 154-166, 1990.
  26. Malison RT, **Price LH**. Panic states. Curr Opin Psychiatry, 3:229-234, 1990.
  27. Goodman WK, McDougle CJ, **Price LH**, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypothesis: A role for dopamine in some forms of obsessive compulsive disorder?. J Clin Psychiatry 51(8, suppl):36-43, 1990.

28. **Price LH**, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR. Clinical studies of 5-HT function using i.v. L-tryptophan. Prog Neuro-Psychopharmacol & Biol Psychiatry 14:459-472, 1990.
29. **Price LH**. Serotonin reuptake inhibitors in depression and anxiety: An overview. Ann Clin Psychiatry 2:165-172, 1990.
30. Charney DS, Delgado PL, **Price LH**, Heninger GR. The receptor sensitivity hypothesis of antidepressant action: A review of antidepressant effects on serotonin function. Chapter in: The Role of Serotonin in Psychiatric Disorders, Brown S-L, Van Praag HM (eds), Brunner/Mazel, New York, NY, pp 27-56, 1991.
31. Goodman WK, **Price LH**, Woods SW, Charney DS. Pharmacologic challenges in obsessive-compulsive disorder. Chapter in: The Psychobiology of Obsessive Compulsive Disorder, Zohar J, Insel T, Rasmussen S (eds), Springer Publishing, New York, pp 162-186, 1991.
32. Malison RT, **Price LH**. Panic disorder: Neurobiological advances. Curr Opin Psychiatry 4:255-261, 1991.
33. Charney DS, Delgado PL, Southwick SM, Krystal JH, **Price LH**, Heninger GR. Current hypotheses of the mechanism of antidepressant treatments: Implications for the treatment of refractory depression. Chapter in: Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression, Amsterdam JD (ed), Raven Press, New York, pp 23-40, 1991.
34. Goodman WK, **Price LH**. Fluvoxamine in the treatment of obsessive-compulsive disorder. Chapter in: Current Treatments of Obsessive-Compulsive Disorder, Pato MT, Zohar J (eds), American Psychiatric Press, Washington, DC, pp 45-59, 1991.
35. Woods SW, O'Malley S, Martini BL, McDougle CJ, **Price LH**, Krystal JH, Hoffer PB, Kosten TR. SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: Preliminary results. Prog Neuro-Psychopharmacol & Biol Psychiatry 15:649-662, 1991.
36. Delgado PL, **Price LH**, Miller HL, Salomon RM, Licinio J, Krystal JH, Heninger GR, Charney DS. Rapid serotonin depletion as a provocative challenge test for patients with major depression: Relevance to antidepressant action and the neurobiology of depression. Psychopharm Bull 27:321-330, 1991.
37. Barr LC, Goodman WK, **Price LH**, McDougle CJ, Charney DS. The serotonin hypothesis of obsessive compulsive disorder: Implications of pharmacologic challenge studies. J Clin Psychiatry 53(4, suppl):17-28, 1992.
38. Goodman WK, McDougle CJ, **Price LH**. Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 53(4, suppl):29-37, 1992.
39. McDougle CJ, Goodman WK, **Price LH**. New research on the neurobiology of obsessive compulsive disorder. Curr. Opin. Psychiatry 5:249-254, 1992.
40. Delgado PL, **Price LH**, Heninger GR, Charney DS. Neurochemistry. Chapter in: Handbook of Affective Disorders, 2nd Ed, Paykel ES (ed), Churchill Livingstone, Edinburgh, UK, pp 219-253, 1992.
41. Black J, McDougle CJ, **Price LH**. Clinical neurobiology of cocaine administration and abstinence. Chapter in: Clinician's Guide to Cocaine Addiction: Theory, Research, and Treatment, Kosten TR, Kleber HD (eds), Guilford Publications, New York, pp 151-171, 1992.
42. Heninger GR, Delgado PL, Charney DS, **Price LH**, Aghajanian GK. Tryptophan-deficient diet and amino acid drink deplete plasma tryptophan and induce a relapse of depression in susceptible patients. J Chem Neuroanat 5:347-348, 1992.
43. Goodman WK, McDougle CJ, **Price LH**. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Internat Clin Psychopharmacology 7(suppl 1):35-38, 1992.
44. Goodman WK, **Price LH**. Assessment of severity and change in obsessive compulsive disorder. Chapter in: Obsessional Disorders. In the series: Psychiatric Clinics of North America, Vol 15(4), Jenike MA (ed), WB Saunders, Philadelphia, pp 861-869, 1992.
45. Redmond DE Jr, Robbins RJ, Naftolin F, Marek KL, Vollmer TL, Leranath C, Roth RH, **Price LH**, Gjedde A, Bunney BS, Sass KJ, Elsworth JD, Kier EL, Makuch R, Hoffer PB, Gulanski BI, Serrano C, Spencer DD. Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: Preliminary results in four patients. Chapter in: Molecular and Cellular Approaches to the Treatment of Neurological Disease. In the series: Research Publications: Assoc

- for Research in Nerv and Mental Dis, Vol 1, Waxman SG (ed), Raven Press, New York, pp 325-359, 1993.
46. McDougle CJ, Goodman WK, **Price LH**. The pharmacotherapy of obsessive compulsive disorder. Pharmacopsychiatry 26(suppl):24-29, 1993.
  47. Goodman WK, McDougle CJ, Barr LC, Aronson S, **Price LH**. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 54(6, suppl):16-26, 1993.
  48. Sherman TS, McDougle CJ, **Price LH**. Paroxetine: A new serotonin reuptake inhibitor for the treatment of depression. Conn Med 57:587-592, 1993.
  49. McDougle CJ, Goodman WK, Leckman JF, **Price LH**. The psychopharmacology of obsessive compulsive disorder: Implications for treatment and pathogenesis. Chapter in: Psychopharmacology II. In the series: Psychiatric Clinics of North America, Vol 16(4), Dunner DL (ed), WB Saunders, Philadelphia, pp 749-766, 1993.
  50. Barr LC, Goodman WK, **Price LH**. The serotonin hypothesis of obsessive compulsive disorder. Internat Clin Psychopharmacology 8(suppl 2):79-82, 1993.
  51. McDougle CJ, **Price LH**, Volkmar FR. Recent advances in the pharmacotherapy of autism and related conditions. Chapter in: Psychoses and Pervasive Developmental Disorders. In the series: Child and Adolescent Psychiatric Clinics of North America, Vol 3(1), Volkmar FR (ed), WB Saunders, Philadelphia, pp 71-89, 1994.
  52. McDougle CJ, Goodman WK, **Price LH**. Dopamine antagonists in tic-related and psychotic spectrum OCD. J Clin Psychiatry 55(3, suppl):24-31, 1994.
  53. Goodman WK, Rasmussen SA, Foa E, **Price LH**. Obsessive compulsive disorder. Chapter in: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines, Prien RF, Robinson DS (eds), Raven Press, New York, pp 431-466, 1994.
  54. **Price LH**, Goddard AW, Barr LC, Goodman WK. Pharmacological challenges in anxiety disorders. Chapter in: Psychopharmacology: The Fourth Generation of Progress, Bloom FE, Kupfer DJ (eds), Raven Press, New York, pp 1311-1323, 1995.
  55. **Price LH**, Malison RT, McDougle CJ, Pelton GH. Antiglucocorticoids as treatments for depression: Rationale for use and therapeutic potential. CNS Drugs 5:311-320, 1996.
  56. Capiello A, **Price LH**. Lithium in the treatment of refractory depression. J Irish Coll Phys Surg 25:194-197, 1996.
  57. Carpenter L, McDougle CJ, Epperson NE, **Price LH**. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Safety 15(2):116-134, 1996.
  58. **Price LH**, Rasmussen SA. Stress and depression: Is neuroimmunology the missing link? Harvard Rev Psychiatry 5:108-112, 1997.
  59. **Price LH**, Carpenter LL. The use of antiglucocorticoids for treating depression. Medscape Ment Health 2(8), <<http://www.medscape.com/>>, 1997.
  60. Goodman WK, **Price LH**. Rating scales for obsessive-compulsive disorder. Chapter in: Obsessive Compulsive Disorders: Practical Management, 3rd Ed, Jenike MJ, Baer L, Minichiello WE (eds), Mosby, Inc., St. Louis, MO, pp 97-117, 1998.
  61. **Price LH**, Malison RT, McDougle CJ, Pelton GH. Antiglucocorticoids as treatments for depression: Rationale for use and therapeutic potential. Chapter in: Disease Management Review - Depression, Adis International, Auckland, NZ, I: pp 99-108, 1998.
  62. **Price LH**, Lemmond K, Carpenter LC. Refractory depression: Assessment and treatment. Directions in Psychiatry 19:1-20, 1999.
  63. Leckman JF, McDougle CJ, Pauls DL, Peterson BS, Grice DE, King RA, Scahill L, **Price LH**, Rasmussen SA. Tic-related versus non-tic-related obsessive-compulsive disorder. Chapter in: Obsessive-Compulsive Disorder: Contemporary Issues in Treatment, Goodman WK, Rudorfer MV, Maser JD (eds), Lawrence Erlbaum Associates, Mahwah, NJ, pp 43-68, 2000.
  64. McDougle CJ, Epperson NE, **Price LH**. The role of neuroleptics in treatment-refractory obsessive-compulsive disorder. Chapter in: Obsessive-Compulsive Disorder: Contemporary Issues in Treatment, Goodman WK, Rudorfer MV, Maser JD (eds), Lawrence Erlbaum Associates, Mahwah, NJ, pp 371-391, 2000.
  65. Carpenter LL, **Price LH**. Psychotic depression: What is it and how should we treat it? Harvard Rev Psychiatry 8:40-42, 2000.
  66. Stuart GL, **Price LH**. Recent developments in populations at risk for substance abuse. Curr Opin Psychiatry 13:315-320, 2000.

67. Goodman WK, **Price LH**, Stein DJ. Fluvoxamine. Chapter in: Current Treatments of Obsessive-Compulsive Disorder, Pato MT, Zohar J (eds), American Psychiatric Publishing, Washington, DC, pp 55-67, 2001.
68. **Price LH**, Carpenter LL, Rasmussen SA. Drug combination strategies. Chapter in: Treatment-Resistant Mood Disorders, Amsterdam JD, Hornig M, Nierenberg AA (eds), Cambridge University Press, Cambridge, UK, pp 194-222, 2001.
69. Phillips KA, **Price LH**, Greenberg BD, Rasmussen SA. Should the DSM diagnostic groupings be changed? Chapter in: Advancing DSM: Dilemmas in Psychiatric Diagnosis, Phillips KA, First MB, Pincus HA (eds), American Psychiatric Association, Washington, DC, pp 57-84, 2003.
70. Greenberg BD, **Price LH**, Rauch SL, Friehs G, Noren G, Malone D, Carpenter LL, Rezaei AR, Rasmussen SA. Neurosurgery for intractable obsessive-compulsive disorder and depression: Critical issues. Chapter in: Surgery for Psychiatric Disorders, Rezaei AR, Rasmussen SA, Greenberg BD (eds). In the series: Neurosurgery Clinics of North America, Vol 14(2), WB Saunders, Philadelphia, pp 199-212, 2003.
71. Carpenter LL, Friehs G, **Price LH**. Cervical vagus nerve stimulation for treatment resistant depression. Chapter in: Surgery for Psychiatric Disorders. In the series: Neurosurgery Clinics of North America, WB Saunders, Philadelphia, pp 275-282, 2003.
72. de Mello AAF, de Mello MF, Jurueña M, Carpenter LL, **Price LH**. A Psiconeuroendocrinologia no Transtorno de Estresse Pós-traumático [The psychoneuroendocrinology of posttraumatic stress disorder]. Chapter in: Transtornos de Estresse Pós-Traumático – TEPT [Posttraumatic Stress Disorder – PTSD], Mari JJ, Mello MF, Bressan RA, Andreoli SB (eds), Editora Manole, Sao Paulo, Brazil, 2005.
73. Carpenter LL, Friehs GM, Tyrka AR, Rasmussen S, **Price LH**, Greenberg BD. Vagus nerve stimulation and deep brain stimulation for treatment resistant depression. Medicine & Health/Rhode Island 89(4):137-141, 2006.
74. Tyrka AR, Carpenter LL, Carvalho JP, **Price LH**. Biomarkers in the human stress system: Do they signal risk for depression? Medicine & Health/Rhode Island 89(5):180-182, 2006.
75. Tyrka AR, **Price LH**, Mello MF, Mello AF, Carpenter LL. Psychotic major depression: A benefit-risk assessment of treatment options. Drug Safety 29(6):491-508. 2006.
76. Mello AF, Jurueña MF, Pariante CM, Tyrka AR, **Price LH**, Carpenter LL, Del Porto JA. Depression and stress: Is there an endophenotype? Rev Bras Psiquiatr 29(Suppl 1):S13-18, 2007.
77. Park MC, Goldman MA, Carpenter LL, **Price LH**, Friehs GM. Vagus nerve stimulation for depression: rationale, anatomical and physiological basis of efficacy and future prospects. Acta Neurochir Suppl 97(Pt 2):407-416, 2007.
78. Philip N, Carpenter LL, Tyrka AR, **Price LH**. Using atypical antipsychotics to augment treatment of nonpsychotic unipolar depression. Directions in Psychiatry 29(1):51-59, 2009.
79. Mello MF, Faria AA, Mello AAF, Carpenter LL, Tyrka AR, **Price LH**. Childhood maltreatment and adult psychopathology: Pathways to hypothalamic-pituitary-adrenal axis dysfunction. Rev Bras Psiquiatr 31(Suppl 2):S41-48, 2009.
80. **Price LH** (field editor for clinical psychopharmacology). In: Encyclopedia of Psychopharmacology, Stolerman I (ed), Springer, Berlin/Heidelberg, Germany, 2010.
81. **Price LH**. Major and minor and mixed anxiety-depressive disorders. Essay in: Encyclopedia of Psychopharmacology, Stolerman I (ed), Springer, Berlin/Heidelberg, Germany, pp 745-749, 2010.
82. Khoury LM, Carpenter LL, **Price LH**, Tyrka AR. Early-life stress and altered neuroendocrine function: Risk for mood and anxiety disorders. Directions in Psychiatry 30(2):63-75, 2010.
83. **Price LH**, Whiteley L. Effective pharmacotherapy for obsessive-compulsive disorder in adults. European Psychiatr Rev 3(2):58-62, 2010.

#### Miscellaneous:

1. **Price LH**. Diagnosing depression with DST. Consultant 23(2):25-26, 1983.
2. **Price LH**. Tricyclic maintenance for depression. Consultant 23(3):27, 1983.
3. **Price LH**. Tricyclics--single v multiple dosing. Consultant 23(7):29-31, 1983.
4. **Price LH**. Therapy for stress reaction. Consultant 23(10):27-28, 1983.

5. **Price LH**, Charney DS, Heninger GR. Manic symptoms following addition of lithium to antidepressant treatment [Ltr to the Ed]. J Clin Psychopharmacol 4:361-362, 1984.
6. **Price LH**. Another use for clonidine. Consultant 24(2):268, 1984.
7. **Price LH**. Megavitaminosis can be depressing. Consultant 24(3):300, 1984.
8. **Price LH**. Unexplained burning sensation. Consultant 26(3):14-15, 1986.
9. **Price LH**. Anxiety vs. depression--how to tell them apart. Consultant 26(6):15-16, 1986.
10. **Price LH**, Nelson JC. Alcoholism and affective disorder [Ltr to the Ed]. Am J Psychiatry 143:1067-1068, 1986.
11. **Price LH**. Mania induced by lithium augmentation [Ltr to the Ed]. Am J Psychiatry 144:389, 1987.
12. Palumbo JM, **Price LH**. Opening the mouth to abolish auditory hallucinations [Ltr to the Ed]. Am J Psychiatry 145:767, 1988.
13. Charney DS, **Price LH**, Brier, A. In reply to "The course of panic attacks and agoraphobia" [Ltr to the Ed]. Arch. Gen. Psychiatry 45:502, 1988.
14. **Price LH**, Heninger GR. Question the Experts: Can yohimbine be used to treat the orthostatic hypotension associated with the use of desipramine and other antidepressants? J Clin Psychopharmacol 8:384, 1988.
15. Goodman WK, **Price LH**. Guidelines to the diagnosis of obsessive compulsive disorder. Anafranil Treatment Program Ciba-Geigy, 1988.
16. **Price LH**. Book review of The Measurement of Depression by Marsella AJ, et al (eds). J Nerv Ment Dis 176:701, 1988.
17. Seibyl JP, Krystal JH, **Price LH**, Charney DS. Use of yohimbine to counteract nortriptyline-induced orthostatic hypotension [Ltr to the Ed]. J Clin Psychopharmacol 9:67-68, 1989.
18. **Price LH**. Question the Experts: What is the duration for augmentation with T<sub>3</sub> or lithium in resistant depression? J Clin Psychopharmacol 9:73, 1989.
19. **Price LH**, Goodman, WK. Obsessive-compulsive disorder: A treatment review [Ltr to the Ed]. J Clin Psychiatry 50:231-232, 1989.
20. Kosten TR, Krystal JH, Charney DS, **Price LH**, Morgan CH, Kleber HD. Rapid detoxification from opioid dependence [Ltr to the Ed]. Am J Psychiatry 146:1349, 1989.
21. McDougle CJ, Goodman WK, Delgado PL, **Price LH**. Pathophysiology of obsessive-compulsive disorder [Ltr to the Ed]. Am J Psychiatry 146:1350-1351, 1989.
22. **Price LH**, Krystal JH, Heninger GR, Ricaurte GA. In reply to "Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity" [Ltr to the Ed]. Arch Gen Psychiatry 47:289, 1990.
23. **Price LH**, Charney DS, Delgado PL, Heninger GR. In reply to "Lithium treatment effect on serotonin function" [Ltr to the Ed]. Arch Gen Psychiatry 47:290, 1990.
24. **Price LH**. When physical complaint persists despite negative workup. Consultant 31(2):13, 1991.
25. Goodman WK, **Price LH**. In reply to "Desensitization of terminal 5-HT autoreceptors by 5-HT reuptake blockers" [Ltr to the Ed]. Arch Gen Psychiatry 48:484, 1991.
26. **Price LH**. Chronic headache of unknown origin. Consultant 31(7):14-15, 1991.
27. McCance-Katz EF, **Price LH**. Depression associated with vitamin A intoxication [Ltr to the Ed]. Psychosomatics 33:117-118, 1992.
28. Kosten TR, **Price LH**. Commentary: Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 180:353-354, 1992.
29. **Price LH**, Charney DS, Heninger GR. Serotonin syndrome [Ltr to the Ed]. Am J Psychiatry 149:1116-1117, 1992.
30. **Price LH**, Delgado PL, Charney DS, Heninger GR. In reply to "Serotonin function in depression: Effects of seasonality?" [Ltr to the Ed]. Am J Psychiatry 149:1277, 1992.
31. Barr LC, Goodman WK, **Price LH**. Acute exacerbation of body dysmorphic disorder during tryptophan depletion [Ltr to the Ed]. Am J Psychiatry 149:1406-1407, 1992.
32. **Price LH**. The treatment of refractory depression: Role of the serotonin reuptake inhibitors. Can Rev Affect Disord 2(4):1-3, 1992.
33. **Price LH**. Concern for self-injury in bipolar disorder. Consultant 33(6):28, 1993.
34. Delgado P, Charney DS, **Price LH**. In reply to "Risk of tryptophan depletion following amino acid supplementation" [Ltr to the Ed]. Arch Gen Psychiatry 50:1000-1001, 1993.
35. Barr LC, Goodman WK, **Price LH**. Physical symptoms associated with paroxetine discontinuation [Ltr to the Ed]. Am J Psychiatry 151:289, 1994.

36. **Price LH**, Heninger GR. In reply to "Lithium in the treatment of mood disorders" [Ltr to the Ed]. N Engl J Med 332:128, 1995.
37. **Price LH**. Coactive pharmacologic strategies for the management of refractory depression. Can Rev Affect Disord, 5(3):1-8, 1995.
38. Nelson JC, **Price LH**. Lithium or desipramine augmentation of fluoxetine treatment [Ltr to the Ed]. Am J Psychiatry 152:1538-1539, 1995.
39. **Price LH**. Mood disorders: Approaching the millenium. Yale Psychiatry 5(1):3-4, 1995.
40. **Price LH**, Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR. In reply to "Responses to mCPP stimulation in depressed patients" [Ltr to the Ed]. Am J Psychiatry 152:1834-1835, 1995.
41. Brodtkin ES, Pelton GH, **Price LH**. Treatment of clozapine-induced parotid gland swelling [Ltr to the Ed]. Am J Psychiatry 153:445, 1996.
42. McDougle CJ, Epperson CN, **Price LH**. Obsessive-compulsive symptoms with neuroleptics [Ltr to the Ed]. J Am Acad Child Adolesc Psychiatry 35(7):837-838, 1996.
43. Epperson CN, McDougle CJ, **Price LH**. Intranasal oxytocin in trichotillomania [Ltr to the Ed]. Biol Psychiatry 40:559-560, 1996.
44. **Price LH**. Review of "The growth hormone response to apomorphine at 4 days postpartum in women with a history of major depression. McIvor RJ, et al. *J Affect Disord* 1996;40:131-136." J Dep Disord: Index Rev 2(1):5, 1997.
45. **Price LH**. Review of "Increased prolactin response to buspirone in chronic fatigue syndrome. Sharpe M, et al. *J Affect Disord* 1996;41:71-76." J Dep Disord: Index Rev 2(1):5, 1997.
46. **Price LH**. Review of "Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the m-opioid-receptor gene. Matthes HWD, et al. *Nature* 1996;383:819-823." J Dep Disord: Index Rev 2(1):7, 1997.
47. **Price LH**. Review of "Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Spina M, et al. *Science* 1996;273:1561-1564." J Dep Disord: Index Rev 2(1):11, 1997.
48. **Price LH**. Review of "Epidemiological data suggest antidepressants reduce suicide risk among depressives. Isacson G, et al. *J Affect Disord* 1996;41:1-18." J Dep Disord: Index Rev 2(1):12, 1997.
49. **Price LH**. Review of "Evidence-based health policy--Lessons from the global burden of disease study. Murray CJL, Lopez AD. *Science* 1996;274:740-744." J Dep Disord: Index Rev 2(1):15, 1997.
50. Malison RT, **Price LH**, Nestler E J, Heninger GR, Duman RS. Efficacy of papaverine addition for treatment-refractory major depression [Ltr to the Ed]. Am J Psychiatry 154:579-580, 1997.
51. **Price LH**. Tele-Lecture Clinics: Augmentation strategies in refractory depression: An update. J Dep Disord: Index Rev 2(3):8-9, 1997.
52. **Price LH**. Review of "Association between the tryptophan hydroxylase gene and manic-depressive illness. Bellivier F, et al. *Arch Gen Psychiatry* 1998;55:33-37." J Dep Disord: Index Rev 3(2):13, 1998.
53. **Price LH**. Review of "Effects of tryptophan depletion in drug-free depressed patients who responded to total sleep deprivation. Neumeister A, et al. *Arch Gen Psychiatry* 1998;55:167-172." J Dep Disord: Index Rev 3(2):13, 1998.
54. **Price LH**. Review of "Electroencephalographic sleep profiles before and after cognitive behavior therapy of depression. Thase ME, et al. *Arch Gen Psychiatry* 1998;55:138-144." J Dep Disord: Index Rev 3(2):14, 1998.
55. **Price LH**. Review of "Epidemiology of recurrent major and minor depression with a seasonal pattern. The National Comorbidity Survey. Blazer DG, et al. *Br J Psychiatry* 1998;172:164-167." J Dep Disord: Index Rev 3(2):14, 1998.
56. **Price LH**. Review of "A factor analysis of the signs and symptoms of mania. Cassidy YF, et al. *Arch Gen Psychiatry* 1998;55:27-32." J Dep Disord: Index Rev 3(2):15, 1998.
57. **Price LH**. Review of "Hormonal and subjective responses to intravenous *m*-chlorophenylpiperazine in women with seasonal affective disorder. Levitan RD, et al. *Arch Gen Psychiatry* 1998;55:244-249." J Dep Disord: Index Rev 3(2):15, 1998.
58. **Price LH**, Rasmussen SA, Eisen JL. The natural history of obsessive-compulsive disorder [Commentary]. Arch Gen Psychiatry 56:131-132, 1999.

59. Gordon A, **Price LH**. Mood stabilization and weight loss with topiramate [Ltr to the Ed]. Am J Psychiatry 156:968-969, 1999.
60. **Price LH**. Commentary on "Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. Kulin NA, et al. JAMA 1998;279:609-610." Evid-based Healthcare 3:43, 1999.
61. Phillips KA, Rasmussen SA, **Price LH**. Treating imagined ugliness [Commentary]. Arch Gen Psychiatry 56:1041-1042, 1999.
62. **Price LH**, Lebel J. Dextromethorphan-induced psychosis [Ltr to the Ed]. Am J Psychiatry 157:304, 2000.
63. Nelson JC, Nierenberg A, **Price LH**. Augmentation strategies in treatment-resistant depression. Psychiatric Update 20(2):1-9, 2000.
64. **Price LH**, Flach F. Interview: Treatment of refractory depression. Essent Psychopharmacology 3(4):71-82, 2000.
65. **Price LH**, Gagne GG Jr, Carpenter LL, Furman MJ. In reply to "Continuation ECT for chronic depression" [Ltr to the Ed]. Am J Psychiatry 158:1933-1934, 2001.
66. Blier P, **Price LH**, Delgado PL. SSRIs vs. SNRIs: Mechanisms of action. CNS Spectrums 6(monogr 12):1-8, 2001 [also in: Primary Psychiatry 8(monogr 12):1-8, 2001].
67. **Price LH**. Book review of Treatment of Recurrent Depression by Greden JF (ed). J Nerv Ment Dis 190(3):204-205, 2002.
68. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 13(4):4, 2002.
69. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 13(5):4, 2002.
70. McDougle CJ, **Price LH**. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent [Ltr to the Ed]. Arch Gen Psychiatry 59(5):472-473, 2002.
71. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 13(7):3, 2002.
72. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 13(9):5, 2002. [Reprinted in: Calif Soc Addict Med. CSAM News 28(3):7, 2003]
73. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 13(12):4, 2002.
74. **Price LH**. "...why are you going into psychiatry?" [Ltr to the Ed]. Medicine at Michigan 4(3):4, 2002.
75. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 14(2):1, 2003.
76. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 14(4):5, 2003.
77. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 14(10):3, 2003.
78. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 15(1):5, 2004.
79. Najjar F, **Price LH**. Citalopram and dystonia [Ltr to the Ed]. J Am Acad Child Adolesc Psychiatry 43(1):8-9, 2004.
80. **Price LH**. Book review of Handbook of Medical Psychiatry by Soares JC and Gershon S (eds). N Engl J Med 350(8):845, 2004.
81. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 15(4):1, 2004.
82. Nelson JC, Mazure CM, Bowers MB, Jr, Jatlow PI, **Price LH**. In reply to "Regarding 'Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind randomized study': Optimizing initial interventions." [Ltr to the Ed]. Biol Psychiatry 56(7):535-536, 2004.
83. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 15(10):5, 2004.
84. **Price LH**. Letter from the editor. Brown Univ Psychopharm Update 15(12):7, 2004.
85. Carpenter LL, Schecter JM, Siniscalchi J, Leon Z, **Price LH**. A case series describing orlistat use in patients on psychotropic medications. Medicine & Health/Rhode Island 87(12):375-377, 2004.
86. **Price LH**. Letter from the editor: Glucose metabolism. Brown Univ Psychopharm Update 16(4):4, 2005.
87. **Price LH**. Book review of Anxiety Disorders in Adults: A Clinical Guide by Starcevic V. N Engl J Med 352(16):1727, 2005.
88. **Price LH**. Letter from the editor: Quetiapine for bipolar disorder. Brown Univ Psychopharm Update 16(9):7, 2005.
89. **Price LH**. Letter from the editor: Comment on the Calabrese et al study. Brown Univ Psychopharm Update 17(2):4, 2006.

90. Wier LM, Tavares SB, Tyrka AR, **Price LH**, Carpenter LL. Levetiracetam-induced depression in a healthy adult [Ltrr to the Ed]. J Clin Psychiatry 67(7):1159-1160, 2006.
91. **Price LH**. Letter from the editor: A roadmap for the STAR\*D studies. Brown Univ Psychopharm Update 17(12):5, 2006.
92. **Price LH**. Editor's commentary: Dopamine agonists and valvular heart disease: The unknown unknowns. Brown Univ Psychopharm Update 18(4):5-6, 2007.
93. **Price LH**. Editor's commentary: Atomoxetine augmentation for depression: Accentuate the negative. Brown Univ Psychopharm Update 18(6):7, 2007.
94. **Price LH**, Tyrka AR. Adjunctive antidepressant treatment for bipolar depression [Ltrr to the Ed]. N Engl J Med 357(6):614, 2007.
95. **Price LH**. Editor's commentary: SSRIs: A risk factor for bone loss? Brown Univ Psychopharm Update 18(10):5, 2007.
96. Spring B, Hitsman B, Baruah S, **Price LH**. In reply to "Interpreting tryptophan depletion in tobacco smokers" [Ltrr to the Ed]. Biol Psychiatry 63(4):e31-e32, 2008.
97. **Price LH**. Editor's commentary: Psychiatric gene testing: Are we ready? Brown Univ Psychopharm Update 19(4):5, 2008.
98. **Price LH**. Editor's commentary: What does a woman want? Brown Univ Psychopharm Update 19(10):6, 2008.
99. **Price LH**. Editor's commentary: Of silk purses and sows ears. Brown Univ Psychopharm Update 19(12):4, 2008.
100. **Price LH**. Editor's commentary: Bad to the bone. Brown Univ Psychopharm Update 20(3):4, 2009.
101. **Price LH**. Editor's commentary: Tough choices on atypicals. Brown Univ Psychopharm Update 20(5):4, 2009.
102. **Price LH**. Atypical antipsychotic drugs and the risk of sudden cardiac death [Ltrr to the Ed]. N Engl J Med 360(20):2137, 2009.
103. **Price LH**. Editor's commentary: A different kind of stimulus package. Brown Univ Psychopharm Update 20(9):3, 2009.
104. **Price LH**. Editor's commentary: When received wisdom fails: Psychotherapy for treatment-resistant depression. Brown Univ Psychopharm Update 21(2):4-5, 2010.
105. **Price LH**. Looking at ways to treat depression [Ltrr to the Ed]. New York Times, January 12, 2010.
106. **Price LH**. Editor's commentary: Preventing PTSD. Brown Univ Psychopharm Update 21(4):5, 2010.
107. Tyrka AR, **Price LH**, Carpenter LL, Anderson GM. In reply to: "Childhood maltreatment and hypothalamic-pituitary-adrenal axis reactivity" [Ltrr to the Ed]. Biol Psychiatry 67(11):e61-e62, 2010.
108. **Price LH**. Editor's commentary: How many antidepressants does it take to treat depression? Brown Univ Psychopharm Update 21(6):5, 2010.
109. Tyrka AR, **Price LH**, Kao H-T, Porton B, Carpenter LL. In reply to: "No correlation between childhood maltreatment and telomere length" [Ltrr to the Ed]. Biol Psychiatry 68(6):e23-24, 2010.
110. Nierenberg AA, Leon AC, **Price LH**, Shelton RC, Trivedi MH. Commentary: The current crisis of confidence in antidepressants. J Clin Psychiatry. In press.